Ironwood Pharmaceuticals Inc. on Monday said that its new drug for irritable bowel syndrome with constipation is now available in the United States, marketed as Linzess (the trade name for linaclotide). It is estimated that irritable bowel syndrome afflicts 30 million to 40 million Americans. The stock rose Monday, fell Tuesday and Wednesday, then gained 3.2 percent Thursday. On Tuesday, Zacks upgraded the shares to “outperform,” with a $12 target price, Jagsreport.com said.
Ironwood stock posts a 3.3 percent gain
December 21, 2012
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢